Navigation Links
Masimo to Present at 24th Annual ROTH Conference
Date:2/27/2012

IRVINE, Calif., Feb. 27, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 24th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point, Calif. on Monday, March 12, 2012, at 2 p.m. Pacific Time.  A live audiocast of the presentation will be available on the Masimo website at www.masimo.com.  A replay of the audiocast will be available following the live presentation.

About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® Pulse CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ...by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statement
This press release includes forward-looking statements based on current expectations about future events affecting us, all of which are subject to risks and uncertainties, difficult to predict and could cause our actual results to differ materially and adversely. These include statements about our technology, focus and prospects, among others. Risks and uncertainties include those related to our technology, competition and intellectual property protection, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact:
Sheree Aronson
Vice President, Investor Relations
Masimo Corporation
(949) 297-7043
saronson@masimo.com                                                                                         

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.


'/>"/>
SOURCE Masimo Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns
2. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
3. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
4. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
5. Masimo to Report Third Quarter 2009 Financial Results on November 3, 2009
6. New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology
7. New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood
8. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
9. St.Vincent Hospital Renews Multi-Year, System-wide Contract for Masimo SET(R) Pulse Oximetry Technology
10. Masimo Expands its Irvine, California Corporate Headquarters to Accommodate Growth Projections
11. Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Pharmaceutical Packaging ... over the next decade to reach approximately $129.81 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:3/22/2017)... -- Piramal Pharma Solutions (PPS), a leading ... event to introduce the new and expanded manufacturing capabilities ... . The inaugural event was attended by Governor ... and Piramal Pharma Solutions CEO, Vivek Sharma . ... ...
(Date:3/22/2017)... Mass. , March 22, 2017 Hologic, ... it has completed the acquisition of Cynosure, Inc., a ... per share in cash. "We are pleased ... to working with Michael Davin and the ... the large, rapidly growing medical aesthetics market," said ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... The ... PCSK9 inhibitor prior authorization (PA) form for prescribers to improve patients’ access to ... the helpful tools published as part of the article entitled “PCSK9 Inhibitor ...
(Date:3/22/2017)... ... March 22, 2017 , ... Donor Network ... Nevada and LABS, Inc., announced the future opening of a CLIA certified dedicated ... serology testing used to determine the suitability of potential organ and tissue ...
(Date:3/22/2017)... Birmingham, Ala. (PRWEB) , ... March 22, 2017 ... ... consumer experience solution provider, today announced that its digital marketing solutions have enabled ... their marketing investment in 24 months. , Recognizing the value of a ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson ... new patients in need of skilled pediatric dentistry in Rock Hill, SC, ... pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a comfortable and ...
(Date:3/22/2017)... ... ... Last year, 43 million gallons of surplus milk was reportedly dumped by ... dairy can be caused by several factors, one pharmaceutical company CEO suggests high rates ... lactose, a sugar found in milk and milk products. It is estimated ...
Breaking Medicine News(10 mins):